

NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION OR RELEASE IN THE UNITED STATES

ASX Announcement 16 November 2020

ELIXINOL GLOBAL RAISES A\$8.2 MILLION VIA A PLACEMENT AND LAUNCHES SHARE PURCHASE PLAN

Key Highlights

- Successful Placement raising A\$8.2 million (before costs) at A\$0.17 per share
- Strong support from new and existing institutional and sophisticated investors
- Following completion of the Placement, Elixinol Global will also conduct a share purchase plan to existing eligible shareholders to raise up to A\$2.0 million
- Proceeds from the Placement and share purchase plan will be used for working capital to support the Company's growth strategy

Elixinol Global Limited (**Elixinol Global** or the **Company**) (**ASX:EXL; OTC:ELLXF**) is pleased to announce the successful completion of a placement to raise A\$8.2 million at A\$0.17 per share (**Placement**) via the issue of 48,209,265 fully paid ordinary shares (**Shares**).

The Placement was supported by both existing and new sophisticated and institutional shareholders. The Shares to be issued under the Placement will rank equally with existing shares in Elixinol Global and are scheduled to be allotted Friday, 20 November 2020.

Elixinol is also pleased to announce that the Company will undertake a share purchase plan (**SPP**) to eligible existing shareholders who have a registered address in Australia or New Zealand as at 7:00pm (Sydney time) on Friday, 13 November 2020. The SPP will provide each eligible shareholder the opportunity to apply for up to A\$30,000 of Shares. Shares issued under the SPP will rank equally with existing Elixinol Global ordinary shares on issue. Elixinol Global is aiming to raise up to A\$2.0 million under the SPP however the Company reserves the right to increase the size of the SPP should there be strong demand from investors. The SPP may also be subject to scale back of applications at the absolute discretion of the Company.

Further information in relation to the SPP, including SPP terms and conditions, will be set out in the SPP offer booklet, expected to be dispatched to eligible shareholders on Friday, 20 November 2020. The Company reserves the right to vary the SPP offer details without notice.

Executive Director and Group CEO of Elixinol Global, Oliver Horn commented, "We greatly appreciate the support of both existing and new investors, with demand for the placement far



exceeding the funds raised. The Board also feels it important to offer new shares to existing shareholders under the same terms as the placement, so have launched a Share Purchase Plan. This funding will be instrumental to Elixinol as we continue to move the Company towards a cash flow positive position - we have recently made significant progress and I feel very positive about the long term prospects for the Company."

The funds raised from the Placement and SPP will be used for working capital to support the Company's growth strategy.

The price for the Placement and SPP represents a discount of:

- 8.1% to the last traded price of \$0.185; and
- 17.7% to the 10 day VWAP of \$0.206.

Under the Placement, the Company will issue 28,925,559 Shares pursuant to ASX Listing Rule 7.1 and 19,283,706 Shares are being issued pursuant to ASX Listing Rule 7.1A. All of the Shares will rank equally with the Company's existing ordinary shares on issue.

Record date for SPP	7.00pm (AEST) Friday, 13 November 2020
Announcement of the Placement and SPP	Monday, 16 November 2020
and lodgment of Appendix 3B and trading	
resumes	
Settlement of Placement	Thursday, 19 November 2020
Issue and allotment of shares pursuant to	Friday, 20 November 2020
Placement, lodgment of Appendix 2A and	
cleansing notice	
SPP opening date and dispatch of SPP offer	Friday, 20 November 2020
booklet to eligible shareholders	
SPP closing date	Friday, 11 December 2020
Announcement of SPP offer results	Wednesday, 16 December 2020
Issue and allotment of shares under the SPP	Friday, 18 December 2020
and lodgment of Appendix 2A	
Dispatch of holding statements	Monday, 21 December 2020

Indicative timetable for the Placement and SPP

The timetable is indicative only and is subject to change. The Company may alter the dates above, withdraw or vary the SPP, or accept SPP applications that are received after the SPP closing date, in each case in the Company's absolute discretion, subject to the ASX Listing Rules and the *Corporations Act 2001* (Cth).

Bell Potter Securities Limited and MST Financial Services Pty Ltd were Joint Lead Managers to the Placement.



This document was authorised to be given to the ASX by the Board of the Company.

For more information please contact:

Ron Dufficy Chief Financial Officer ron.dufficy@elixinolglobal.com

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTC:ELLXF) is a global leader in the hemp industry, innovating, marketing and selling hemp derived nutraceutical and food products. The Company's simplified business model is focusing on:

- In the Americas, innovating, marketing and selling high quality Elixinol branded hemp derived nutraceutical products based in Colorado, USA
- In Europe and the UK, educating and selling high quality Elixinol branded and co-branded hemp derived nutraceutical and skincare products based in Utrecht, The Netherlands and London, UK
- In Australia, providing stronger unified planning and support across the group to enable the various regional offices to focus on operational strategy and execution through its Global Executive Office based in Sydney, Australia
- Hemp Foods Australia Pty Ltd (Hemp Foods Australia), a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products
- Across the Rest of World, expanding distribution of Elixinol branded hemp derived products through reputable distributors as key markets open.

See more at <u>www.elixinolglobal.com</u>